An Observational Multi Center Study to Evaluate Real World Treatment Outcomes of Durvalumab Based Regimens in Hepatobiliary Cancers
Latest Information Update: 11 Jun 2025
At a glance
- Drugs Cisplatin (Primary) ; Durvalumab (Primary) ; Gemcitabine (Primary) ; Tremelimumab (Primary)
- Indications Biliary cancer; Liver cancer
- Focus Therapeutic Use
- Acronyms LIVER-R
- Sponsors AstraZeneca
Most Recent Events
- 25 Nov 2024 Planned End Date changed from 13 Dec 2029 to 30 Dec 2030.
- 25 Nov 2024 Planned primary completion date changed from 13 Dec 2029 to 30 Dec 2030.
- 25 Mar 2024 Planned number of patients changed from 2490 to 4490.